Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-freeInterval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis
Main Article Content
Keywords
aryl hydrocarbon receptor agonist, AhR, tapinarof cream 1% once daily, atopic dermatiits, pruritis
Abstract
- Tapinarof (VTAMA®, Dermavant Sciences, an Organon Company) is a non-steroidal, topical aryl hydrocarbon receptor (AhR)
agonist approved by the FDA for the treatment of atopic dermatitis (AD) in adults and children down to 2 years of age, and for the
treatment of plaque psoriasis in adults2
- Tapinarof binds to and activates AhR to restore the skin barrier by upregulating key barrier components, downregulating
pro-inflammatory cytokines associated with AD, and reducing oxidative stress (Figure 1)1
- Discontinuation of topical therapy for AD may be associated with rapid return of disease1
- Preventative maintenance with topicals may be a significant treatment burden for patients and caregivers1,3,4
- In the ADORING 3 long-term trial, adults and children with AD received tapinarof cream 1% once daily (QD)5
- Patients entered with or achieved complete disease clearance (51.9%; Validated Investigator Global Assessment for Atopic
Dermatitis™ [vIGA-AD™]=0) and clear or almost clear skin (81.6%; vIGA-AD™=0 or 1)5
- After discontinuing tapinarof per protocol, patients maintained clear or almost clear skin for 79.8 (mean) consecutive days
(first treatment-free interval)5
References
2. Dermavant Sciences. VTAMA® (tapinarof) cream, 1%: US prescribing information; 2024. Available at: https://
www.vtama.com/PI/. Accessed September 2025.
3. Eichenfield LF, et al. J Am Acad Dermatol. 2014;71:116–132.
4. Chovatiya R, Silverberg JI. Dermatitis. 2022;33:S17–S23.
5. Bissonnette R, et al. J Am Acad Dermatol. 2025.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.